BROOKS vs PPLPHARMA: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. BROOKS LAB shows a higher ROE, lower leverage and a higher ROCE, while PIRAMAL PHARMA shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BROOKS leads 8; PPLPHARMA leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BROOKS | PPLPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BROOKS | PPLPHARMA |
|---|---|---|
| Live Price | ₹59.09 | ₹214.66 |
| Day Change | -3.97% | 3.12% |
| Volume | 86,961 | 43.31 L |
| 52-Week High | ₹153.99 | ₹231.93 |
| 52-Week Low | ₹36.3 | ₹132.3 |
| Distance from 52W High | -61.63% | -7.45% |
Valuation
| Metric | BROOKS | PPLPHARMA |
|---|---|---|
| Market Cap | ₹175 Cr | ₹28,551 Cr |
| P/E Ratio | 8.22x | 0x |
| P/B Ratio | 1.65x | 3.41x |
| EPS | ₹4.49 | ₹0.85 |
| Book Value | ₹41.64 | ₹61.31 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | BROOKS | PPLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | -6.37% | -0.1% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | -50.44% |
| Qtr Profit Growth | 179.39% | 263.54% |
Profitability & Leverage
| Metric | BROOKS | PPLPHARMA |
|---|---|---|
| ROE | 4.8% | -3.99% |
| ROCE | 5.46% | -0.66% |
| Net Margin | 28.67% | -3.68% |
| Operating Margin | 7.74% | 1.21% |
| Debt to Equity | 0.06x | 0.67x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BROOKS | PPLPHARMA |
|---|---|---|
| Promoter Holding | 52.62% | 34.8%▼ 0.06 pp |
| FII Holding | 0%▼ 0.17 pp | 12.52%▼ 17.66 pp |
| DII Holding | 10.38% | 14.57%▼ 1.04 pp |
| Public Holding | 37%▲ 0.16 pp | 37.63%▲ 18.62 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BROOKS LAB and PIRAMAL PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.